Exact Sciences is committed to supporting patient access to the Oncotype DX AR-V7 Nucleus Detect test to help your patients make informed decisions about their treatment.
Financial Responsibility Information
Out-of-pocket costs for the Oncotype DX AR-V7 Nucleus Detect test, if any, are determined by the insurance company. Patients may have financial responsibility for a co-pay, co-insurance, deductible or non-covered charges as determined by their insurance plan once available appeal options are completed. The numbers* cited below are based on historical patient billing data:
of Oncotype DX AR-V7 Nucleus Detect test patients have $0 financial responsibility
This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid and commercial insurance. Patient cost-sharing amounts, including deductibles and copays will vary by plan and coverage type. Only your patient’s insurer can confirm if and how the Oncotype DX AR-V7 Nucleus Detect test will be covered.
of Oncotype DX AR-V7 Nucleus Detect test patients have a financial responsibility of <$100
This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid and commercial insurance. Patients with high-deductible plans may receive a bill for most or all the cost of the Oncotype DX AR-V7 Nucleus Detect test if they have not satisfied their deductible.
* The numbers cited are based on historical patient billing data from 1/02/2020 to 12/31/2020. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about Oncotype DX AR-V7 Nucleus Detect test coverage.
Exact Sciences strongly encourages patients to contact their insurer when they have questions about their benefits. Regardless of network status, all commercial insurance coverage is governed by an insurer’s medical policy and patient benefit type.
Patients with fee for service (FFS) Medicare will have $0 financial responsibility if they meet coverage requirements (see below). Patients with Medicare Advantage, which is provided by a commercial insurance company, may have different financial responsibility amounts than patients with FFS Medicare. If your patient’s out-of-pocket amount is $500 or more as determined by the patient’s insurance, they will receive a call from our Exact Sciences’ billing team to discuss payment options. We will also submit secondary or supplemental insurance claims on your patient’s behalf if the necessary information was submitted with the order. If your patient receives a bill and is not sure if a claim was submitted to their secondary or supplemental insurance, please have your patient contact us.
FFS Medicare, Medicare Advantage and several private insurance carriers cover the Oncotype DX AR-V7 Nucleus Detect test for eligible patients with metastatic castration-resistant prostate cancer (mCRPC). Exact Sciences† is an in-network provider with many health plans, including Aetna, Anthem, Cigna, Humana and UnitedHealthcare. Since insurance coverage can vary across the country, it’s a good idea to check with your patient’s carrier or contact the Customer Service team to confirm coverage. The Oncotype DX AR-V7 Nucleus Detect test is reported on claims with the unique Current Procedural Terminology (CPT) code, 81479.
Oncotype DX AR-V7 Nucleus Detect is now covered by Medicare for your mCRPC patients
Partnering with You & Your Patients
Genomic Access Program (GAP)
Exact Sciences believes that everyone should have access to the information they need to make confident, informed decisions about their cancer treatments. To advance this mission, we created GAP to help patients navigate and understand the insurance and billing process for the Oncotype tests. The GAP team can:
- Work with clinicians to get prior authorization from insurance companies (if required).
- Bill insurance companies directly when possible.
- Process the claim once the test is complete.
- With your patient’s consent, assist in the appeal process if a claim is denied.
- Contact insurance companies on patients’ behalf.
Download in other languages: Spanish | Traditional Chinese | Simplified Chinese
For faster results, complete your requisition form online on the Physician Portal as insurance can be verified and most required forms can be pre-filled and completed online. If you do not have an online ordering account, sign up today.
Exact Sciences offers financial assistance programs for eligible patients with financial hardship. These programs are based on financial eligibility.
- Financial assistance is available for eligible patients who are uninsured and may be available for insured patients unable to pay the out-of-pocket amount determined by their insurance.
- Eligibility is based on Federal poverty guidelines, and we proactively contact all uninsured patients to determine eligibility for financial assistance. Payment plans may also be available.
- Financial assistance is not available if the patient has insurance coverage but elects to be billed directly instead of billing insurance.
Patients may also contact us before the test is ordered or during the testing process to review available payment terms or to be pre-screened for financial assistance. To learn more, contact our Customer Service by phone at ( 866-ONCOTYPE866-662-6897, option 2) or message us for more information.
The Medicare 14-Day Rule
FFS Medicare has specific date of service reporting requirements for laboratory tests, and the technical component of physician pathology services, ordered for Medicare patients (commonly known as the “14-Day Rule”). The 14-Day Rule determines whether the laboratory performing the test bills Medicare directly or bills the hospital where the specimen was collected.
In general, Medicare requires that laboratories bill the hospital when the test is ordered less than 14 days following a patient’s inpatient or outpatient hospital stay (when the specimen was collected). However, as of January 1, 2018, the 14-day rule does not apply to molecular pathology tests when the specimen is collected from a hospital outpatient, regardless of order date.
We process test orders as they are received from providers. Clinical judgment should be the determining factor for test ordering.
See Medicare Specific Coverage Criteria
Local Coverage Determination (LCD): MolDX: Androgen Receptor Variant (AR-V7) Protein Test (L37701)
See the full LCD
Coverage Indications, Limitations, and/or Medical Necessity
This contractor will provide limited coverage for an Androgen Receptor splice variant 7 messenger RNA protein test (AR-V7) to help determine which patients with metastatic castrate resistant prostate cancer or other androgen receptor containing tumors may benefit from androgen receptor signaling inhibitor therapy and which may benefit from chemotherapy.
AR-V7 is covered as follows:
- Patients will have progressive mCRPC as defined by the Prostate Cancer Working Group 2 guidelines (a minimum of 2 rising prostate-specific antigen (PSA) levels 1 or more weeks apart, new lesions by bone scintigraphy, and/or new or enlarging soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI)).
- Patients will have failed one ARSi, (presently Enzalutamide (Xtandi), Apalutamide (Erleada), or Abiraterone (Zytiga) and future similar class drugs approved by the FDA).
- Patients will be considered appropriate for treatment by their treating physician for the alternative ARSi as a single agent.
- Circulating tumor cells (CTC) with nuclear expression of AR-V7 protein will be assessed prior to initiation of therapy.
- Decision impact analysis: We expect that < 15% of nuclear AR-V7-positive patients will receive an ARSi.
- Efficacy analysis: Nuclear AR-V7-negative patients who receive an ARSi will have similar or better time on therapy than untested mCRPC patients (meeting above criteria) receiving an ARSi.
- Other Androgen Receptor variant tests that demonstrate an equivalent analytical validity and clinical validity will be considered reasonable and necessary for similar diagnoses and criteria listed below indications. Analytical and clinical validity will be assessed as part of a thorough and comprehensive technical assessment (TA) by the MolDx program and will similarly attain coverage for indications that are supported by the evidence and intended use within the scope of this policy.